Articles

More Alzheimer’s answers

UPenn team publishes research on epigenetic roots of Alzheimer’s disease
Brought to you byDDNews Staff
| 3 min read

PHILADELPHIA—New findings suggest that late-onset Alzheimer’s disease is driven by epigenetic changes—how and when certain genes are turned on and off—in the brain.

Research led by three members of the Perelman School of Medicine at the University of Pennsylvania—Raffaella Nativio, a former research associate of epigenetics; Shelley Berger, a professor of genetics, biology and cell and developmental diology and director of the Epigenetics Institute; and Nancy Bonini, a professor of biology and cell and developmental biology—used post-mortem brain tissue to compare healthy younger and older brain cells to those with Alzheimer’s disease. The team found evidence that epigenetic regulators disable protective pathways and enable pro-disease pathways in those with the disease and published their results in Nature Genetics.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.